INSULIN-SENSITIZING AGENT AND BUTYRATE-PRODUCING BACTERIUM
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 15, 2024
app pub date -
May 25, 2022
filing date -
May 28, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
This disclosure is concerned with a combination comprising at least one butyrate-producing bacterium and at least one insulin-sensitizing agent for use in the prevention and/or treatment of metabolic disease, insulin resistance and insulin resistance-related conditions, preferably chosen from type 1 diabetes mellitus, type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, insulin resistance in endocrine disease, Polycystic Ovary Syndrome (PCOS), Nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). The insulin-sensitizing agent and the butyrate-producing bacterium, at least in part, have a synergistic effect on lowering insulin resistance in subjects.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully